INmune Average Inventory vs Price To Sales Ratio Analysis

INMB Stock

USD 4.99 0.09 1.77%

INmune Bio financial indicator trend analysis is infinitely more than just investigating INmune Bio recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether INmune Bio is a good investment. Please check the relationship between INmune Bio Average Inventory and its Price To Sales Ratio accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.

Average Inventory vs Price To Sales Ratio

Average Inventory vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of INmune Bio Average Inventory account and Price To Sales Ratio. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between INmune Bio's Average Inventory and Price To Sales Ratio is -0.41. Overlapping area represents the amount of variation of Average Inventory that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of INmune Bio, assuming nothing else is changed. The correlation between historical values of INmune Bio's Average Inventory and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Average Inventory of INmune Bio are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Average Inventory i.e., INmune Bio's Average Inventory and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

-0.41

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Average Inventory

The average amount of inventory a company holds over a certain period, which is used to calculate inventory turnover and efficiency in managing stock levels.

Price To Sales Ratio

Price to Sales Ratio is figured by comparing INmune Bio stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on INmune Bio sales, a figure that is much harder to manipulate than other INmune Bio multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Most indicators from INmune Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into INmune Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.At present, INmune Bio's Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 710.64, whereas Selling General Administrative is forecasted to decline to about 6.4 M.

	2010	2023	2024 (projected)
Interest Income	77.7K	69.9K	62.2K
Net Interest Income	77.7K	69.9K	62.2K

Interest Income Net Interest Income

INmune Bio fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Net Debt	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Short Long Term Debt	Short Term Debt	Net Invested Capital	Net Working Capital	Intangible Assets	Retained Earnings Total Equity
Total Assets		-0.08	0.6	0.99	0.92	-0.78	0.72	0.98	0.98	0.87	0.88	0.98	0.31	0.92	-0.97	0.9	0.93	0.85	0.0	0.95	0.72	0.44	0.97	0.95	-0.25	-0.86
Other Current Liab	-0.08		-0.25	-0.02	-0.29	0.22	-0.23	-0.26	-0.26	-0.18	-0.29	-0.26	-0.19	-0.3	0.25	-0.23	-0.04	-0.35	0.53	-0.13	0.31	-0.27	-0.28	-0.27	0.18	0.29
Total Current Liabilities	0.6	-0.25		0.54	0.81	-0.96	0.98	0.56	0.56	0.9	0.86	0.57	0.91	0.7	-0.58	0.56	0.74	0.83	-0.12	0.76	0.71	0.98	0.57	0.49	-0.86	-0.9
Total Stockholder Equity	0.99	-0.02	0.54		0.89	-0.74	0.67	0.96	0.96	0.84	0.83	0.96	0.26	0.87	-0.96	0.87	0.91	0.79	0.04	0.92	0.72	0.37	0.95	0.94	-0.22	-0.81
Net Tangible Assets	0.92	-0.29	0.81	0.89		-0.92	0.9	0.92	0.92	0.97	0.96	0.92	0.61	0.91	-0.95	0.8	0.91	0.9	-0.1	0.93	0.71	0.69	0.93	0.89	-0.57	-0.94
Retained Earnings	-0.78	0.22	-0.96	-0.74	-0.92		-0.99	-0.74	-0.74	-0.98	-0.94	-0.75	-0.8	-0.82	0.76	-0.71	-0.89	-0.91	0.05	-0.9	-0.79	-0.9	-0.75	-0.68	0.74	0.97
Accounts Payable	0.72	-0.23	0.98	0.67	0.9	-0.99		0.69	0.69	0.96	0.93	0.69	0.86	0.79	-0.71	0.65	0.83	0.88	-0.11	0.85	0.76	0.93	0.7	0.62	-0.81	-0.94
Cash	0.98	-0.26	0.56	0.96	0.92	-0.74	0.69		1.0	0.83	0.88	1.0	0.28	0.94	-0.99	0.89	0.88	0.86	-0.08	0.92	0.59	0.4	0.99	0.98	-0.22	-0.84
Cash And Short Term Investments	0.98	-0.26	0.56	0.96	0.92	-0.74	0.69	1.0		0.83	0.88	1.0	0.28	0.94	-0.99	0.89	0.88	0.86	-0.08	0.92	0.59	0.4	0.99	0.98	-0.22	-0.84
Capital Surpluse	0.87	-0.18	0.9	0.84	0.97	-0.98	0.96	0.83	0.83		0.96	0.84	0.72	0.87	-0.86	0.78	0.93	0.91	-0.03	0.94	0.81	0.81	0.84	0.79	-0.67	-0.97
Total Liab	0.88	-0.29	0.86	0.83	0.96	-0.94	0.93	0.88	0.88	0.96		0.89	0.63	0.96	-0.88	0.86	0.87	0.96	-0.14	0.92	0.67	0.77	0.89	0.85	-0.59	-0.98
Total Current Assets	0.98	-0.26	0.57	0.96	0.92	-0.75	0.69	1.0	1.0	0.84	0.89		0.27	0.95	-0.98	0.92	0.88	0.87	-0.09	0.92	0.59	0.41	0.99	0.98	-0.21	-0.85
Common Stock	0.31	-0.19	0.91	0.26	0.61	-0.8	0.86	0.28	0.28	0.72	0.63	0.27		0.41	-0.33	0.18	0.52	0.58	-0.1	0.51	0.62	0.94	0.28	0.2	-0.95	-0.66
Short Long Term Debt Total	0.92	-0.3	0.7	0.87	0.91	-0.82	0.79	0.94	0.94	0.87	0.96	0.95	0.41		-0.91	0.92	0.85	0.95	-0.15	0.91	0.57	0.58	0.95	0.92	-0.34	-0.92
Net Debt	-0.97	0.25	-0.58	-0.96	-0.95	0.76	-0.71	-0.99	-0.99	-0.86	-0.88	-0.98	-0.33	-0.91		-0.86	-0.87	-0.83	0.07	-0.9	-0.6	-0.43	-0.99	-0.98	0.3	0.84
Net Receivables	0.9	-0.23	0.56	0.87	0.8	-0.71	0.65	0.89	0.89	0.78	0.86	0.92	0.18	0.92	-0.86		0.79	0.85	-0.11	0.85	0.49	0.43	0.92	0.9	-0.16	-0.85
Common Stock Total Equity	0.93	-0.04	0.74	0.91	0.91	-0.89	0.83	0.88	0.88	0.93	0.87	0.88	0.52	0.85	-0.87	0.79		0.89	0.05	0.99	0.88	0.62	0.85	0.8	-0.39	-0.9
Common Stock Shares Outstanding	0.85	-0.35	0.83	0.79	0.9	-0.91	0.88	0.86	0.86	0.91	0.96	0.87	0.58	0.95	-0.83	0.85	0.89		-0.25	0.93	0.67	0.74	0.85	0.79	-0.47	-0.96
Other Current Assets	0.0	0.53	-0.12	0.04	-0.1	0.05	-0.11	-0.08	-0.08	-0.03	-0.14	-0.09	-0.1	-0.15	0.07	-0.11	0.05	-0.25		-0.01	0.17	-0.14	-0.1	-0.09	0.1	0.1
Other Stockholder Equity	0.95	-0.13	0.76	0.92	0.93	-0.9	0.85	0.92	0.92	0.94	0.92	0.92	0.51	0.91	-0.9	0.85	0.99	0.93	-0.01		0.82	0.64	0.9	0.85	-0.4	-0.94
Short Long Term Debt	0.72	0.31	0.71	0.72	0.71	-0.79	0.76	0.59	0.59	0.81	0.67	0.59	0.62	0.57	-0.6	0.49	0.88	0.67	0.17	0.82		0.62	0.55	0.49	-0.49	-0.72
Short Term Debt	0.44	-0.27	0.98	0.37	0.69	-0.9	0.93	0.4	0.4	0.81	0.77	0.41	0.94	0.58	-0.43	0.43	0.62	0.74	-0.14	0.64	0.62		0.42	0.33	-0.89	-0.81
Net Invested Capital	0.97	-0.28	0.57	0.95	0.93	-0.75	0.7	0.99	0.99	0.84	0.89	0.99	0.28	0.95	-0.99	0.92	0.85	0.85	-0.1	0.9	0.55	0.42		0.99	-0.26	-0.85
Net Working Capital	0.95	-0.27	0.49	0.94	0.89	-0.68	0.62	0.98	0.98	0.79	0.85	0.98	0.2	0.92	-0.98	0.9	0.8	0.79	-0.09	0.85	0.49	0.33	0.99		-0.19	-0.79
Intangible Assets	-0.25	0.18	-0.86	-0.22	-0.57	0.74	-0.81	-0.22	-0.22	-0.67	-0.59	-0.21	-0.95	-0.34	0.3	-0.16	-0.39	-0.47	0.1	-0.4	-0.49	-0.89	-0.26	-0.19		0.6
Retained Earnings Total Equity	-0.86	0.29	-0.9	-0.81	-0.94	0.97	-0.94	-0.84	-0.84	-0.97	-0.98	-0.85	-0.66	-0.92	0.84	-0.85	-0.9	-0.96	0.1	-0.94	-0.72	-0.81	-0.85	-0.79	0.6

Click cells to compare fundamentals

INmune Bio Account Relationship Matchups

INmune Bio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	24.5M	40.7M	99.9M	81.8M	57.0M	41.6M
Total Current Liabilities	700.4K	1.8M	4.4M	10.9M	18.5M	19.4M
Total Stockholder Equity	23.6M	38.8M	80.2M	60.1M	38.1M	33.6M
Net Tangible Assets	7.1M	22.2M	63.7M	43.6M	50.1M	52.6M
Retained Earnings	(21.3M)	(33.4M)	(63.7M)	(91.0M)	(121.0M)	(115.0M)
Accounts Payable	692.1K	1.5M	3.8M	5.2M	7.9M	8.3M
Cash	7.0M	22.0M	74.8M	52.2M	35.8M	23.6M
Cash And Short Term Investments	7.0M	22.0M	74.8M	52.2M	35.8M	23.6M
Capital Surpluse	44.8M	72.1M	143.9M	151.8M	174.6M	183.3M
Total Liab	860.5K	1.9M	19.7M	21.7M	18.9M	19.8M
Total Current Assets	7.8M	24.0M	82.6M	64.7M	39.9M	27.2M
Common Stock	8.7K	10.8K	13.5K	18K	817K	857.9K
Net Debt	(6.8M)	(21.8M)	(59.6M)	(36.8M)	(25.4M)	(26.7M)
Non Current Assets Total	16.7M	16.7M	17.3M	17.1M	17.1M	16.2M
Net Receivables	645.4K	1.8M	5.5M	8.5M	2.4M	2.8M
Common Stock Total Equity	8.7K	10.8K	13.5K	18K	20.7K	12.9K
Common Stock Shares Outstanding	10.3M	12.0M	16.1M	17.9M	18.0M	14.8M
Liabilities And Stockholders Equity	24.5M	40.7M	99.9M	81.8M	57.0M	46.8M
Non Current Liabilities Total	160.2K	126.3K	15.4M	10.8M	397K	377.2K
Other Current Assets	769.3M	220K	2.3M	4.1M	1.7M	1.6M
Other Stockholder Equity	44.9M	72.1M	143.9M	151.8M	159.1M	85.4M
Accumulated Other Comprehensive Income	(8.5K)	10.7K	1K	(699K)	(799K)	(759.1K)
Net Invested Capital	23.6M	38.8M	94.7M	74.8M	48.1M	49.4M
Net Working Capital	7.1M	22.2M	78.2M	53.8M	21.5M	29.0M
Retained Earnings Total Equity	(21.3M)	(33.4M)	(63.7M)	(91.0M)	(81.9M)	(77.8M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:

How To Invest In INmune

Details

Is INmune Stock a good investment?

Details

What is INmune Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.

You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.18)

Revenue Per Share

0.002

Quarterly Revenue Growth

(0.63)

Return On Assets

(0.45)

Return On Equity

(0.99)

The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

INmune Average Inventory vs Price To Sales Ratio Analysis

Average Inventory vs Price To Sales Ratio

Average Inventory vs Price To Sales Ratio Correlation Analysis

Correlation Coefficient

Average Inventory

Price To Sales Ratio

INmune Bio fundamental ratios Correlations

INmune Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

INmune Bio fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Net Invested Capital	+ 0.99	Cash
Net Invested Capital	+ 0.99	Cash And Short Term Investments

Net Invested Capital	- 0.99	Net Debt
Net Debt	- 0.99	Cash And Short Term Investments
Net Debt	- 0.99	Cash
Accounts Payable	- 0.99	Retained Earnings
Net Working Capital	- 0.98	Net Debt
Net Debt	- 0.98	Total Current Assets